These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25894871)

  • 1. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?
    Aoki Y; Douglas AG; Wood MJ
    Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871
    [No Abstract]   [Full Text] [Related]  

  • 2. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?
    Mizielinska S; Isaacs AM
    Curr Opin Neurol; 2014 Oct; 27(5):515-23. PubMed ID: 25188012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyotrophic lateral sclerosis and gene therapy.
    Miller TM; Smith RA; Cleveland DW
    Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
    [No Abstract]   [Full Text] [Related]  

  • 4. Tofersen: First Approval.
    Blair HA
    Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Mutations in SOD1 and C9orf72 Genes on Autophagy in Lymphomonocytes in Myotrophic Lateral Sclerosis.
    Kochergin IA; Shpilyukova YA; Lysogorskaia EV; Abramycheva NY; Zakharova MN; Illarioshkin SN
    Bull Exp Biol Med; 2019 Sep; 167(5):667-670. PubMed ID: 31625064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
    Friedrich MJ
    JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].
    Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH
    Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.
    Chiò A; Borghero G; Restagno G; Mora G; Drepper C; Traynor BJ; Sendtner M; Brunetti M; Ossola I; Calvo A; Pugliatti M; Sotgiu MA; Murru MR; Marrosu MG; Marrosu F; Marinou K; Mandrioli J; Sola P; Caponnetto C; Mancardi G; Mandich P; La Bella V; Spataro R; Conte A; Monsurrò MR; Tedeschi G; Pisano F; Bartolomei I; Salvi F; Lauria Pinter G; Simone I; Logroscino G; Gambardella A; Quattrone A; Lunetta C; Volanti P; Zollino M; Penco S; Battistini S; ; Renton AE; Majounie E; Abramzon Y; Conforti FL; Giannini F; Corbo M; Sabatelli M
    Brain; 2012 Mar; 135(Pt 3):784-93. PubMed ID: 22366794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
    Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
    Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined fulminant frontotemporal dementia and amyotrophic lateral sclerosis associated with an I113T SOD1 mutation.
    Katz JS; Katzberg HD; Woolley SC; Marklund SL; Andersen PM
    Amyotroph Lateral Scler; 2012 Oct; 13(6):567-9. PubMed ID: 22670877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion.
    Sathyaprakash C; Manzano R; Varela MA; Hashimoto Y; Wood MJA; Talbot K; Aoki Y
    Methods Mol Biol; 2020; 2176():185-208. PubMed ID: 32865792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic architecture of amyotrophic lateral sclerosis and frontotemporal dementia : Overlap and differences].
    Synofzik M; Otto M; Ludolph A; Weishaupt JH
    Nervenarzt; 2017 Jul; 88(7):728-735. PubMed ID: 28573364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference and amyotrophic lateral sclerosis.
    Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
    Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 16. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
    Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is SOD1 loss of function involved in amyotrophic lateral sclerosis?
    Saccon RA; Bunton-Stasyshyn RK; Fisher EM; Fratta P
    Brain; 2013 Aug; 136(Pt 8):2342-58. PubMed ID: 23687121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population.
    Vrabec K; Koritnik B; Leonardis L; Dolenc-Grošelj L; Zidar J; Smith B; Vance C; Shaw C; Rogelj B; Glavač D; Ravnik-Glavač M
    Neurobiol Aging; 2015 Mar; 36(3):1601.e17-20. PubMed ID: 25585530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to Gene Modulation Therapy for ALS.
    Meijboom KE; Brown RH
    Neurotherapeutics; 2022 Jul; 19(4):1159-1179. PubMed ID: 36068427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.